Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 4c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.68), $0.04 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Draganfly wins Canadian Armed Forces drone contract for up to 5,000 units
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance